Close Menu

Browsing: HCP Access Only 1

Upadacitinib (Rinvoq): Once-Daily Oral Treatment for Rheumatoid Arthritis (RA)

By KayeMarch 17, 20220

Fremanezumab (Ajovy): Migraines – A True Pain to Treat

By EmmaMarch 11, 20220

Paxlovid (Nirmatrelvir and Ritonavir) by Pfizer – A Game-changer in the COVID-19 Treatment Landscape?

By Alyssa YapMarch 3, 20220

Singapore’s HSA New Drugs and Indications Approval – Jan 2022

By Sian LinFebruary 24, 20220

HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)

By KayeFebruary 17, 20220

Finerenone (Kerendia) – A new therapeutic agent in the Diabetic Kidney Disease (DKD) treatment paradigm

By KayeFebruary 10, 20220

Eptinezumab (Vyepti) for preventive treatment of both episodic and chronic migraine

By EmmaFebruary 2, 20220

Singapore’s HSA New Drugs and Indications Approval – Dec 2021

By Sian LinJanuary 25, 20220

The growing biologic armamentarium of plaque psoriasis treatment: A review of risankizumab (Skyrizi)

By KayeJanuary 20, 20220

Singapore’s HSA ADR News Bulletin – Dec 2021

By Alyssa YapJanuary 18, 20220

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

What's Hot

Tun Dr Mahathir Hospitalised for Lung Infection at Heart Institute

Sunscreens: Topical or Oral?

“It’s Better to Know Early”: Malay Women in Singapore Face Lowest Breast Cancer Screening Rates

Browsing: HCP Access Only 1

Upadacitinib (Rinvoq): Once-Daily Oral Treatment for Rheumatoid Arthritis (RA)

Fremanezumab (Ajovy): Migraines – A True Pain to Treat

Paxlovid (Nirmatrelvir and Ritonavir) by Pfizer – A Game-changer in the COVID-19 Treatment Landscape?

Singapore’s HSA New Drugs and Indications Approval – Jan 2022

HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)

Finerenone (Kerendia) – A new therapeutic agent in the Diabetic Kidney Disease (DKD) treatment paradigm

Eptinezumab (Vyepti) for preventive treatment of both episodic and chronic migraine

Singapore’s HSA New Drugs and Indications Approval – Dec 2021

The growing biologic armamentarium of plaque psoriasis treatment: A review of risankizumab (Skyrizi)

Singapore’s HSA ADR News Bulletin – Dec 2021

Tun Dr Mahathir Hospitalised for Lung Infection at Heart Institute

Sunscreens: Topical or Oral?

“It’s Better to Know Early”: Malay Women in Singapore Face Lowest Breast Cancer Screening Rates

Mammograms: The Most Reliable Detector of Breast Cancer

Subscribe to Updates

What's Hot

Browsing: HCP Access Only 1

Subscribe to Updates